2020
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communication
2018
The adverse kidney effects of cancer immunotherapies
Saly D, Perazella M. The adverse kidney effects of cancer immunotherapies. Journal Of Onco-Nephrology 2018, 2: 56-68. DOI: 10.1177/2399369318808806.Peer-Reviewed Original ResearchChronic kidney diseaseKidney diseaseCancer immunotherapyInterleukin-2High-dose interleukin-2Chimeric antigen receptor T cellsAntigen receptor T cellsMore effective treatment optionsAdverse kidney effectsImmune checkpoint inhibitorsAcute kidney diseaseEffective treatment optionReceptor T cellsCase-based reviewCancer therapyGroup of drugsNew cancer immunotherapiesCancer treatment armamentariumConventional chemotherapeutic drugsList of cancersOlder immunotherapiesCheckpoint inhibitorsTreatment armamentariumNew immunotherapiesTreatment options